1313874-96-2

Basic information

• Product Name: Afatinib-d6
• Synonyms: Afatinib-d6;(S,E)-4-(bis(trideuteromethyl)amino)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)but-2-enamide
• CAS NO: 1313874-96-2
• Molecular Formula: C24H19ClD6FN5O3
• Molecular Weight: 491.975373868
• EINECS: 604-604-1
• Mol File: 1313874-96-2.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• CAS DataBase Reference: Afatinib-d6(CAS DataBase Reference)
• NIST Chemistry Reference: Afatinib-d6(1313874-96-2)
• EPA Substance Registry System: Afatinib-d6(1313874-96-2)

Safety Data

• Hazardous Substances Data: 1313874-96-2(Hazardous Substances Data)

Usage

Description

Afatinib-d6, also known as the d6 labeled analogue of Afatinib (A355300), is an aminocrotonylamino-substituted quinazoline derivative. It is primarily used in the field of medical research and pharmaceuticals due to its potential applications in treating various types of cancer and diseases related to the respiratory tract, lungs, gastrointestinal tract, bile duct, and gallbladder.

Uses

Used in Pharmaceutical Industry:
Afatinib-d6 is used as an active pharmaceutical ingredient for the development of drugs targeting cancer and respiratory diseases. Its application is based on its ability to inhibit specific protein tyrosine kinases, which play a crucial role in the growth and survival of cancer cells.
Used in Cancer Treatment:
Afatinib-d6 is used as an anticancer agent for the treatment of various types of cancer, including non-small cell lung cancer, pancreatic cancer, and other solid tumors. It works by targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), which are often overexpressed in cancer cells, leading to uncontrolled cell growth and proliferation.
Used in Respiratory Tract Disease Treatment:
Afatinib-d6 is used as a therapeutic agent for diseases of the respiratory tract, such as asthma and chronic obstructive pulmonary disease (COPD). Its application is based on its ability to inhibit the signaling pathways involved in inflammation and airway constriction, which are common features of these diseases.
Used in Gastrointestinal Tract Disease Treatment:
Afatinib-d6 is used as a treatment option for gastrointestinal tract diseases, such as gastroesophageal reflux disease (GERD) and inflammatory bowel disease (IBD). Its application is due to its potential to modulate the signaling pathways involved in inflammation and cell proliferation, which contribute to the development and progression of these conditions.
Used in Bile Duct and Gallbladder Disease Treatment:
Afatinib-d6 is used as a therapeutic agent for diseases of the bile duct and gallbladder, such as cholangiocarcinoma and gallbladder cancer. Its application is based on its ability to target the molecular pathways involved in the growth and survival of cancer cells in these tissues.